Argireline (Acetyl Hexapeptide-8)

What it is

Acetyl hexapeptide-8, formerly also called acetyl hexapeptide-3 and known under the trade name Argireline, is a short peptide of 6 amino acids. It is modeled on the N-terminal section of the protein SNAP-25. SNAP-25 is part of the machinery with which nerve cells release their messenger substances. Botulinum toxin also acts on exactly this protein, but in a completely different way: it cleaves it.

In cosmetics the substance is freely available and is used as a skin-conditioning agent.

How it is supposed to work

The basis in the laboratory is solidly described. Peptides modeled on the beginning of SNAP-25 inhibit the formation of the SNARE complex and thus calcium-dependent release from cells. In doing so they break apart the binary complex of SNAP-25 and syntaxin. This was studied in cell systems and in nerve cells, not in human skin.

That is exactly where the open question lies. The peptide is water-loving and quite large for a peptide. The stratum corneum of the skin is fat-loving and largely holds back such a molecule. A review on skin penetration concludes that it remains uncertain whether acetyl hexapeptide-8 reaches the neuromuscular end plates at all. Formulations with emulsions are said to improve this. The muscle effect in humans is not established.

That several studies nonetheless measure something therefore need not be due to the muscle. The same review names reduced wrinkle depth, better elasticity and more moisture as observed effects, without knowing the mechanisms behind them.

Applied or injected

In the scene, injections also turn up alongside serums. These are two completely different things, with two completely different bodies of evidence. For injected use there is no efficacy study in humans. A 2026 animal experiment tested it: 40 rats in 4 groups, injection under the skin before creating a skin flap. The collagen profile under Argireline alone could not be distinguished from the saline control, and survival of the skin flap did not differ in any group. The authors note that injected Argireline had no detectable tissue effect under these conditions.

Then there is the risk. A case report describes a 45-year-old woman who had acetyl hexapeptide-8 injected into her forehead and temples. After one week, redness, nodules and abscesses appeared, and Mycobacterium abscessus was detected in the pus. She needed two antibiotics for 5 months until the lesions receded. Cosmetic raw materials are not manufactured sterile to pharmaceutical standards.

What the studies show

Wang et al., Am J Clin Dermatol 2013

Randomized and placebo-controlled, 60 Chinese participants in a ratio of 3 to 1, twice daily over 4 weeks on the fine lines around the eyes. Endpoints: rating on 2 scales and objective analysis of silicone replicas. Result: overall efficacy 48.9 percent versus 0 percent, all roughness parameters decreased. Small, short, one population.

An et al., Ann Dermatol 2019

Double-blind, randomized, split-face, 52 Korean women, 29 days, weekly application of a microneedle patch to the eye area and nasolabial fold. The addition of acetyl hexapeptide-8 improved wrinkles more than the patch alone. Important: here microneedles brought the active ingredient into the skin; it was not simple topical application.

Henseler 2023 (negative finding)

Double-blind split-face comparison, 19 women, the same hyaluronic acid serum on both halves of the face, with Argireline on only one side, 4 weeks, evaluation with camera analysis. The wrinkle score fell slightly on both sides, but not significantly, and there was no difference between the sides. The study is small, but it is the cleanest direct comparison of the same base formulation with and without the active ingredient.

Aruan et al., J Clin Aesthet Dermatol 2023 (direct comparison)

Double-blind and randomized, 21 Indonesian women between 26 and 55 years, 8 weeks, 3 groups: cream with acetyl hexapeptide-3, cream with palmitoyl pentapeptide-4 and placebo, twice daily on the eye area. Measurements were made with several skin measuring devices, photography and a crow’s feet scale. Both active ingredients improved the values in several participants, with the collagen peptide palmitoyl pentapeptide-4 doing better. The authors themselves call it a preliminary study and call for more participants.

Nukaly et al., Front Med 2026 (meta-analysis)

Systematic review of 19 randomized studies with 1,341 participants on peptides against skin aging. Hydration and radiance improved, the pooled effect on wrinkles was small, and it was mainly due to orally taken polypeptides. Tolerability good, effects on elasticity and skin density inconsistent.

Where the data stop

The comparison with botulinum toxin does not hold. What is established is SNARE inhibition in cell systems, not the dampening of facial muscles in humans. Whether the peptide, applied to the skin, gets deep enough at all is open. The study with the clearest design, the split-face comparison with and without the active ingredient in the same base formulation, found no difference and concluded that Argireline is not a substitute for botulinum toxin.

The studies are small and short, between 19 and 60 participants and 4 to 12 weeks. They measure wrinkles and skin values, not hard endpoints. Many positive studies also test finished products with several active ingredients, for example additionally niacinamide or a second peptide. The contribution of the individual peptide cannot be calculated from them. And in the only direct comparison with another cosmetic peptide, a preliminary study in 21 women over 8 weeks, the collagen peptide palmitoyl pentapeptide-4 did better. In a meta-analysis of peptides against skin aging, the wrinkle effect was small overall and was mainly due to orally taken polypeptides.

On concentration, the independent assessment at the upper end is missing: above a concentration of 0.005 percent, the data were insufficient for the US expert panel to make a safety statement. And for injected use there is no efficacy study in humans, no detectable tissue effect in the animal model, and one documented case of infection.

Status, approval and legal

Acetyl hexapeptide-8 is a cosmetic ingredient and freely available in Germany in serums and creams. Its described function is as a skin-conditioning agent. The European ingredient database could not be accessed on September 30, 2026, so we do not give a European maximum concentration here. Cosmetics may not promise a medicinal effect. Anyone promising paralysis of facial expression leaves the framework of cosmetics. As a solution for injection, the substance is not an approved medicine and may not be marketed in Germany; we do not give dosage information for it. In the 2026 Prohibited List the substance is not named explicitly. For an injected, unapproved preparation, according to the wording, the catch-all class S0 for non-approved substances applies.

Safety

Applied to the skin, the substance is well tolerated. In the application studies there were no serious side effects, no allergic reactions and no skin irritation. The US expert panel for the safety of cosmetic ingredients has formally assessed acetyl hexapeptide-8 and considers it safe in current uses up to a concentration of 0.005 percent; for higher concentrations the data were insufficient for a statement. There are no upper limits from EFSA or BfR because the substance is not a food. It has not been studied in pregnancy and breastfeeding. On irritated or injured skin and around the eyes, the same caution applies as with any cosmetic. Injection is a different matter: there are no safety data for it, and the one documented case, an infection with Mycobacterium abscessus after injections into the forehead and temples, required 5 months of antibiotic therapy.

Sources

• Wang et al., Am J Clin Dermatol 2013 (randomized, placebo-controlled)
• An et al., Ann Dermatol 2019 (double-blind split-face study)
• Henseler, GMS Interdiscip Plast Reconstr Surg DGPW 2023 (negative finding)
• Zdrada-Nowak et al., Int J Mol Sci 2025 (skin penetration)
• Blanes-Mira et al., J Neurochem 2004 (SNARE inhibition)
• Johnson et al., Int J Toxicol 2025 (cosmetic safety assessment)
• Nukaly et al., Front Med 2026 (meta-analysis of peptides)
• Acuner et al., Aesthetic Plast Surg 2026 (injected, animal model)
• Chen et al., World J Clin Cases 2021 (case report of infection)
• Aruan et al., J Clin Aesthet Dermatol 2023 (comparison with palmitoyl pentapeptide-4)